Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986165-01 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BMS-985165-01 prototype formulation 1 | EXPERIMENTAL | - |
| BMS-986165 Tablet | EXPERIMENTAL | - |
| BMS-985165-01 prototype formulation 2 | EXPERIMENTAL | - |
| BMS-985165-01 prototype formulation 3 | EXPERIMENTAL | - |
| BMS-985165-01 prototype formulation 3 or 4 | EXPERIMENTAL | - |
| BMS-985165-01 prototype formulation 3, 4 or 5 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986165-01 | DRUG | Participants will receive BMS- 986165 -01 in prototype formulation |
| BMS-986165 Tablet | DRUG | Participants will receive BMS-986165 in tablet form. |
| Famotidine | DRUG | Participants will receive a previously dosed BMS-985165-01 Prototype Tablet at the same dose level following administration of famotidine |
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Patients must be willing and able to complete all study-specific procedures and visits * Healthy patients, as determined by no clinically significant deviati...
BMS-986165-01 is an investigational small molecule being developed for the treatment of lupus. It is currently in Phase 1 clinical development, and it has been studied in a completed clinical trial involving healthy volunteers in the United Kingdom.
BMS-986165-01 is being developed by Bristol-Myers Squibb Company, which is publicly traded under the ticker symbol BMY. The company is conducting clinical research on this investigational small molecule for lupus.
BMS-986165-01 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and pharmacokinetics.
BMS-986165-01 has one completed clinical trial, NCT04065932, titled "A Study to Determine the Pharmacokinetic Profile of BMS-986165 Tablets." This Phase 1 study enrolled 33 participants in the United Kingdom and included healthy volunteers.
BMS-986165-01 is a specific formulation or version of the investigational compound BMS-986165. The clinical trial NCT04065932 evaluated the pharmacokinetic profile of BMS-986165 tablets, which is the drug being developed for lupus.